Article thumbnail

Pharmacological evaluation of rat dorsal root ganglion neurons as an in vitro model for diabetic neuropathy

By Eve Peeraer, An Van Lutsenborg, An Verheyen, Raf De Jongh, Rony Nuydens and Theo F Meert
Topics: Original Research
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:3085264
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. Activating transcription factor 3 (ATF3) induction by axotomy in sensory and motoneurons: A novel neuronal marker of nerve injury.
  2. (1996). Analysis of ATF3, a transcription factor induced by physiological stresses and modulated by gadd153/chop10. Mol Cell Biol.
  3. and stress responses. Gene Expression.
  4. (2002). Anticonvulsants in neuropathic pain: Rationale and clinical evidence.
  5. ATF3 expression in L4 dorsal root ganglion neurons after L5 spinal nerve transaction.
  6. Axonal growth potential of lumbar dorsal root ganglion neurons in an organ culture system.
  7. Contribution of injured and uninjured dorsal root ganglion neurons to pain behavior and the changes in gene expression following chronic constriction injury of the sciatic nerve in rats.
  8. (1991). Cross-family dimerization of transcription factors Fos/Jun and ATF/CREB alters DNA binding specificity.
  9. Development of selective axonopathy in adult sensory neurons isolated from diabetic rats: Role of glucose-induced oxidative stress.
  10. (1947). Diabetes mellitus and its degenerative complications: A prospective study of 4,400 patients observed between
  11. Diabetes- induced expression of activating transcription factor 3 in mouse primary sensory neurons.
  12. (1992). Diabetic and hypoglycaemic neuropathy.
  13. Diabetic peripheral neuropathy. Evidence for apoptosis and associated mitochondrial dysfunction.
  14. Differential ATF3 expression in dorsal root ganglion neurons reveal the profile of primary afferents engaged by diverse noxious chemical stimuli.
  15. (1993). Electrophysiological and pathological characteristics of suramin induced neuropathy. Neurology.
  16. Expression of ATF3 and axonal outgrowth are impaired after delayed nerve repair.
  17. Gabapentin in postherpetic neuralgia.
  18. GDNF rescues nonpeptidergic unmyelinated primary afferents in streptozotocin-treated diabetic mice. Exp Neurol.
  19. (1993). GDNF: A glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons.
  20. (1994). GDNF: A potent survival factor for motoneurons present in peripheral nerve and muscle.
  21. Glial cell line-derived neurotrophic factor normalizes neurochemical changes in injured dorsal root ganglion neurons and prevents the expression of experimental neuropathic pain.
  22. High glucose-induced oxidative stress and mitochondrial dysfunction in neurons.
  23. (2008). Hyperglycaemia inhibits Schwann cell proliferation and migration and restricts regeneration of axons and Schwann cells from adult murine DRG. Mol Cell Neurosci.
  24. (2000). Is there a role for therapeutic drug monitoring of new anticonvulsants? Clin Pharmacokinet.
  25. Nerve compression induces activating transcription factor 3 in neurons and Schwann cells in diabetic rats.
  26. Nerve growth factors (NGF, BDNF) enhance axonal regeneration but are not required for survival of adult sensory neurons.
  27. (2002). Neurobiology of neuropathic pain: Mode of action of anticonvulsants.
  28. (1999). Neurons undergo apoptosis in animal and cell culture models of diabetes. Neurobiol Dis.
  29. (2003). New insights into the metabolic and molecular basis for diabetic neuropathy. Cell Mol Life Sci.
  30. NGF and GDNF ameliorate the increase in ATF3 expression which occurs in dorsal root ganglion cells in response to peripheral nerve injury.
  31. (2004). Oxidative stress in the pathogenesis of diabetic neuropathy. Endocr Rev.
  32. (1996). Pathology and pathogenetic mechanisms of diabetic neuropathy. Diabetes Metab Rev.
  33. Positive and negative interactions of GDNF, NTN and ART in developing sensory neuron subpopulations, and their collaboration with neurotrophins.
  34. (2003). Restorative effects of neurotrophin treatment on diabetes-induced cutaneous axon loss in mice. Exp Neurol.
  35. Short-term hyperglycemia produces oxidative damage and apoptosis in neurons.
  36. Spinal cord compression and dorsal root injury cause up-regulation of activating transcription factor-3 in large-diameter dorsal root ganglion neurons.
  37. (2009). Synergistic effect of GDNF and NGF on axonal branching and elongation in vitro. Neurosci Res.
  38. (1995). The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med.
  39. (1993). The Diabetes Control and Complications Trial Research group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.
  40. (2007). The effect of low-dose insulin on mechanical sensitivity and allodynia in type I diabetes neuropathy. Neurosci Lett.
  41. (2005). The Janus role of c-jun: Cell death versus survival and regeneration of neonatal sympathetic and sensory neurons. Exp Neurol.
  42. The role of growth factors in diabetic peripheral neuropathy.
  43. (2006). The transcription factor ATF-3 promotes neurite outgrowth. Mol Cell Neurosci.
  44. (1997). Tissue-specific pattern of stress kinase activation in ischemic/reperfused heart and kidney.
  45. Uncoupling proteins prevent glucose-induced neuronal oxidative stress and programmed cell death.
  46. (2002). Use of anticonvulsants for the treatment of neuropathic pain.